Hereditary Angioedema: Acute and Prophylactic Treatment
Acute On-Demand Treatment
All HAE attacks should be treated immediately upon recognition, regardless of location or perceived severity, with treatment initiated within the first hour of symptom onset to achieve optimal outcomes. 1, 2
First-Line Acute Therapies
The following medications are effective for acute HAE attacks:
- C1 inhibitor concentrates (plasma-derived: Berinert, Cinryze; recombinant: Ruconest/Conestat alpha) are highly effective and have the best safety profile, particularly for children and pregnant women 3, 4
- Icatibant (bradykinin B2 receptor antagonist) is widely used and approved for self-administration, with attack duration significantly reduced when given early (6.1 hours when treated <1 hour vs 16.8 hours when treated ≥1 hour) 1, 3
- Ecallantide (kallikrein inhibitor) is effective but requires administration under supervision due to risk of anaphylactoid reactions 3, 4
Critical Timing Considerations
- Treat within 1 hour of attack onset whenever possible—this reduces attack duration by approximately 10 hours compared to delayed treatment 1
- Self-administration enables faster treatment (median 41 minutes in recent trials) compared to waiting for healthcare provider administration 1
- All abdominal, facial, oral, and upper airway attacks require immediate treatment 1, 2
- Laryngeal, tongue, or throat attacks require immediate self-treatment AND emergency care due to life-threatening potential 1, 2
Common Pitfall
57% of patients do not treat all attacks, and only 14% treat immediately, often due to misjudging attack severity or waiting to see if symptoms worsen 5. This delay leads to more severe attacks, longer recovery times, and higher recurrence rates (32.7% experience attack return after delayed treatment) 5.
Long-Term Prophylaxis
Lanadelumab (subcutaneous anti-kallikrein monoclonal antibody) is the preferred first-line agent for long-term prophylaxis, offering disease-modifying control with convenient dosing intervals. 6, 7
Long-Term Prophylactic Options (in order of preference)
- Lanadelumab: Subcutaneous kallikrein inhibitor, administered every 2 weeks, represents the most advanced disease-modifying therapy with potential for attack-free remission 6, 3, 7
- Berotralstat: Oral kallikrein inhibitor, offers convenient oral administration for patients preferring this route 6, 3
- C1 inhibitor concentrate (subcutaneous or intravenous): Effective but requires more frequent administration 3, 2
- Danazol (attenuated androgen): Effective but associated with significant adverse effects including virilization, hepatotoxicity, and lipid abnormalities; use limited by safety concerns 6, 3
- Tranexamic acid (antifibrinolytic): Less effective than other options, reserved for patients who cannot use other therapies 6, 3
Emerging Oral Therapies
Sebetralstat (investigational oral plasma kallikrein inhibitor) showed significant efficacy in phase 3 trials, with median time to symptom relief of 1.6-1.8 hours versus 6.7 hours for placebo when administered early (median 41 minutes from onset) 1. This represents a major advance as the first effective oral on-demand therapy.
Short-Term Prophylaxis
C1 inhibitor concentrate is the treatment of choice for preprocedural short-term prophylaxis. 3, 2
- Administer before dental procedures, surgeries, or other known triggers 3, 2
- Alternative: Danazol or fresh frozen plasma (in China where C1-INH unavailable) 7
Special Populations
Pediatric Patients
- Plasma-derived C1 inhibitor has the best evidence of safety and remains first-line for acute treatment in children 4, 8
- Early diagnosis is critical as most cases present before age 18 8
- Younger patients are less likely to carry on-demand treatment, requiring specific education and support 5
Pregnancy and Breastfeeding
- Plasma-derived C1 inhibitor is the safest option with reassuring safety record 4, 7
- Avoid androgens completely during pregnancy and breastfeeding 7
Treatment Goals and Monitoring
The primary objective is achieving attack-free remission or near-complete disease control to minimize impact on quality of life 9, 6, 2. This requires:
- Every patient must have an on-demand treatment plan since all prophylactic agents are associated with breakthrough attacks 4
- Patients should carry on-demand medication at all times 5
- Regular assessment of disease burden and treatment efficacy 2
Critical Safety Note
Antihistamines, corticosteroids, and epinephrine are completely ineffective for HAE attacks as the mediator is bradykinin, not histamine 6, 7. Using these agents delays appropriate treatment and worsens outcomes.